Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenics Pharmaceuticals and Wyeth Pharmaceuticals, a division of Wyeth, have received FDA approval for Relistor subcutaneous injection for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.
Subscribe to our email newsletter
In clinical studies, Relistor significantly decreased the constipating effects of opioids without interfering with pain relief. Wyeth expects to make Relistor available in the US in early June, 2008.
Bernard Poussot, president and CEO of Wyeth, said: “As Wyeth’s third new medicine to receive FDA approval in 2008, Relistor is an excellent example of Wyeth’s continuing commitment to develop and deliver medicines that work in novel ways and provide important new treatment options for patients.”